The argument for pharmaceutical policy

被引:9
|
作者
Traulsen, JM
Almarsdóttir, AB
机构
[1] Danish Univ Pharmaceut Sci, Dept Social Pharm, DK-2100 Copenhagen O, Denmark
[2] Univ Iceland, Fac Pharm, Reykjavik, Iceland
[3] AL BAS Pharmaceut Consultants Ltd, Reykjavik, Iceland
来源
PHARMACY WORLD & SCIENCE | 2005年 / 27卷 / 01期
关键词
health care; pharmaceutical policy; pharmacy administration;
D O I
10.1007/s11096-004-5151-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmaceutical policy is a global concern. It has become a hot political topic in most countries - developed as well as developing - and can be found on the agenda of international organizations such as WHO, OECD, EU, WTO and even the World Bank. Pharmaceutical policy affects everyone in the world of pharmacy and it is therefore imperative that it be understood, discussed and debated within the pharmacy profession and included in the curriculum of schools of pharmacy. This, the first article in a series, argues for the importance of the academic discipline of pharmaceutical policy analysis and the involvement of pharmacists in this endeavour. The aim of the authors is to stimulate an informed and critical appreciation of this field. The authors begin with an introduction to the field of pharmaceutical policy, introducing several important concepts and current trends including: medicines regulation; how pharmaceutical policy is made; pharmaceutical policy as a dynamic process; and the new public health as a global issue. The article ends with a short description of the remaining five articles in the series which will deal with important aspects of pharmaceutical policy. The topics include: economic pressures on health care systems; drug utilization from the clinical viewpoint ( rational use of medicines); the impact of pharmaceutical policy on patients and the patient impact on pharmaceutical policy; the professional perspective; and finally the last article which deals with studying and evaluating pharmaceutical policy.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 50 条
  • [31] Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
    Deborah Gleeson
    Joel Lexchin
    Ronald Labonté
    Belinda Townsend
    Marc-André Gagnon
    Jillian Kohler
    Lisa Forman
    Kenneth C. Shadlen
    Globalization and Health, 15
  • [32] Changing policy focus through organizational reform? The case of the pharmaceutical unit in the European Commission
    Vestlund, Nina Merethe
    PUBLIC POLICY AND ADMINISTRATION, 2015, 30 (01) : 92 - 112
  • [33] Modeling the impact of an outcome-oriented reimbursement policy on clinic, patients, and pharmaceutical firms
    So, KC
    Tang, CS
    MANAGEMENT SCIENCE, 2000, 46 (07) : 875 - 892
  • [34] Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
    Gleeson, Deborah
    Lexchin, Joel
    Labonte, Ronald
    Townsend, Belinda
    Gagnon, Marc-Andre
    Kohler, Jillian
    Forman, Lisa
    Shadlen, Kenneth C.
    GLOBALIZATION AND HEALTH, 2019, 15 (01)
  • [35] Reforms: a quest for efficiency or an opportunity for vested interests’? a case study of pharmaceutical policy reforms in Tanzania
    Amani Thomas Mori
    Eliangiringa Amos Kaale
    Peter Risha
    BMC Public Health, 13
  • [36] Reforms: a quest for efficiency or an opportunity for vested interests'? a case study of pharmaceutical policy reforms in Tanzania
    Mori, Amani Thomas
    Kaale, Eliangiringa Amos
    Risha, Peter
    BMC PUBLIC HEALTH, 2013, 13
  • [37] A Sociotechnical Approach to Analyze Pharmaceutical Policy and Services Management in Primary Health Care in a Brazilian Municipality
    Maria da Bernardo, Noemia Liege
    Soares, Luciano
    Leite, Silvana Nair
    PHARMACY, 2021, 9 (01)
  • [38] Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countries
    Kebriaeezadeh, Abbas
    Koopaei, Nasser Nassiri
    Abdollahiasl, Akbar
    Nikfar, Shekoufeh
    Mohamadi, Nafiseh
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 21
  • [39] Is pharmaceutical policy evidence-informed? A case of the deregulation process of nicotine replacement therapy products in Finland
    Kurko, Terhi
    Silvast, Antti
    Wahlroos, Hannes
    Pietila, Kirsi
    Airaksinen, Marja
    HEALTH POLICY, 2012, 105 (2-3) : 246 - 255
  • [40] Branded Care: The Policy Implications of Pharmaceutical Industry-Funded Nursing Care Related to Specialty Medicines
    Grundy, Quinn
    Huyer, Larkin Davenport
    Parker, Lisa
    Bero, Lisa
    POLICY POLITICS & NURSING PRACTICE, 2023, 24 (01) : 67 - 75